NBRV Nabriva Therapeutics plc Stock Quote

NBRV [NASD]

Index	-	P/E	-	EPS (ttm)	-0.82	Insider Own	1.20%	Shs Outstand	63.24M	Perf Week	5.25%
Market Cap	12.93M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	-6.10%	Shs Float	58.05M	Perf Month	-0.31%
Income	-46.60M	PEG	-	EPS next Q	-0.16	Inst Own	13.10%	Short Float	1.22%	Perf Quarter	-6.54%
Sales	35.30M	P/S	0.37	EPS this Y	78.90%	Inst Trans	0.30%	Short Ratio	0.83	Perf Half Y	-62.22%
Book/sh	0.55	P/B	0.35	EPS next Y	45.20%	ROA	-64.10%	Target Price	2.00	Perf Year	-82.00%
Cash/sh	0.30	P/C	0.65	EPS next 5Y	-	ROE	-95.20%	52W Range	0.16 - 1.40	Perf YTD	-67.54%
Dividend	-	P/FCF	-	EPS past 5Y	66.10%	ROI	-79.70%	52W High	-85.34%	Beta	1.49
Dividend %	-	Quick Ratio	2.00	Sales past 5Y	34.80%	Gross Margin	51.10%	52W Low	31.62%	ATR	0.02
Employees	73	Current Ratio	2.80	Sales Q/Q	12.20%	Oper. Margin	-	RSI (14)	59.11	Volatility	11.39% 9.48%
Optionable	Yes	Debt/Eq	0.21	EPS Q/Q	39.50%	Profit Margin	-	Rel Volume	4.49	Prev Close	0.19
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 03 AMC	Payout	-	Avg Volume	853.23K	Price	0.21
Recom	2.50	SMA20	12.80%	SMA50	7.03%	SMA200	-55.38%	Volume	1,881,771	Change	5.56%

Mar-19-20

Downgrade

Wedbush

Outperform → Neutral

May-02-19

Upgrade

Gabelli & Co

Sell → Hold

May-02-19

Reiterated

H.C. Wainwright

Buy

$9 → $7

Sep-07-18

Resumed

Morgan Stanley

Overweight

Mar-21-18

Initiated

BofA/Merrill

Buy

$10

Jan-17-18

Initiated

Morgan Stanley

Overweight

Nov-01-17

Reiterated

H.C. Wainwright

Buy

$18 → $20

Aug-25-17

Initiated

SunTrust

Buy

$20

Feb-01-17

Reiterated

Wedbush

Outperform

$13

Oct-27-16

Resumed

Leerink Partners

Outperform

$14

Sep-08-16

Initiated

H.C. Wainwright

Buy

$16

Jan-27-16

Initiated

Gabelli & Co

Buy

$14

Nov-12-15

Reiterated

RBC Capital Mkts

Outperform

$21 → $22

Oct-13-15

Initiated

Wedbush

Outperform

Oct-13-15

Initiated

RBC Capital Mkts

Outperform

$21

Oct-13-15

Initiated

Leerink Partners

Outperform

$19

Oct-12-15

Initiated

Needham

Buy

$15

Aug-11-22 07:01AM	Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis GlobeNewswire
Aug-03-22 04:01PM	Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire +8.72%
Jul-20-22 04:05PM	Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022 GlobeNewswire
Jul-18-22 07:01AM	Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals GlobeNewswire
May-13-22 07:01AM	Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire +8.03%
May-05-22 04:01PM	Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire -5.02%
07:01AM	Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026 GlobeNewswire
May-02-22 04:05PM	Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022 GlobeNewswire
Apr-11-22 04:05PM	Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis GlobeNewswire
Mar-29-22 04:01PM	Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update GlobeNewswire
Mar-21-22 08:25AM	uniQure (QURE) Moves 5% Higher: Will This Strength Last? Zacks
Mar-15-22 07:01AM	Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022 GlobeNewswire
Mar-01-22 07:01AM	Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-18-22 04:01PM	Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022 GlobeNewswire
Jan-14-22 04:01PM	Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders GlobeNewswire
Jan-10-22 07:00AM	Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021 GlobeNewswire
Dec-22-21 09:20AM	Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021 GlobeNewswire
Dec-21-21 04:05PM	Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-10-21 10:00AM	Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Nov-29-21 09:00AM	Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia GlobeNewswire
Nov-24-21 10:00AM	Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV) Zacks
Nov-18-21 06:23AM	Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-11-21 07:01AM	Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack GlobeNewswire
Nov-09-21 04:01PM	Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire
Nov-05-21 07:01AM	Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-01-21 07:01AM	Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.22%
Oct-26-21 07:01AM	Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021 GlobeNewswire
Oct-15-21 04:05PM	Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021 GlobeNewswire
Oct-05-21 08:01AM	The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga
Oct-04-21 04:05PM	Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin) GlobeNewswire -5.88%
Oct-01-21 04:05PM	Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
12:35PM	Lab notes: Onconova completes $21M stock sale; Waypoint gets $1.7M investment American City Business Journals
07:01AM	Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer GlobeNewswire
Sep-30-21 08:00AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire
Sep-24-21 07:01AM	Nabriva Therapeutics to Present Data at IDWeek 2021 GlobeNewswire
Sep-16-21 09:03AM	4 Penny Stocks Insiders Are Buying Benzinga +8.49%
Sep-09-21 10:02AM	Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact Benzinga
07:01AM	Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizients Pharmacy Network Program GlobeNewswire
Sep-08-21 07:01AM	Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia GlobeNewswire
Sep-01-21 07:01AM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-31-21 04:05PM	Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-05-21 04:01PM	Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire
08:00AM	Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire
Aug-03-21 04:27PM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.29%
Jul-22-21 07:01AM	Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021 GlobeNewswire
Jul-14-21 10:00AM	Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV) Zacks
Jul-09-21 04:05PM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-18-21 03:03PM	Hedge Funds Never Been Less Bullish On Nabriva Therapeutics plc (NBRV) Insider Monkey
Jun-11-21 05:16AM	When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Turn A Profit? Simply Wall St.
Jun-08-21 11:07AM	Crestone Joins Antimicrobials Working Group PR Newswire
Jun-03-21 07:01AM	Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital GlobeNewswire
Jun-02-21 06:02PM	Nabriva Announces Changes to its Board of Directors GlobeNewswire
Jun-01-21 07:01AM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-26-21 06:53AM	Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China Benzinga
May-25-21 05:00PM	Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP) GlobeNewswire
May-21-21 07:01AM	Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-06-21 04:01PM	Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire -6.88%
02:45PM	Nabriva Therapeutics Plc to Host Earnings Call ACCESSWIRE
May-05-21 11:51AM	Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss Zacks -5.33%
May-03-21 04:05PM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-30-21 10:28AM	Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track Zacks +6.59%
Apr-29-21 04:05PM	Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021 GlobeNewswire
06:03AM	Rising P/E: An Overlooked Way to Pick 5 Winning Stocks Zacks
Apr-15-21 12:12PM	Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S. GlobeNewswire +6.08%
Apr-14-21 09:38AM	Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer Zacks
06:49AM	Rising P/E: An Overlooked Strategy to Pick Winning Stocks Zacks
Apr-09-21 09:40AM	Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF Zacks
Apr-06-21 09:05AM	ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down Zacks
Apr-05-21 06:39AM	5 Best Stocks With Rising P/E to Buy for Solid Returns Zacks
Apr-02-21 04:01PM	Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-01-21 08:17AM	Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD Zacks +5.42%
08:00AM	Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-25-21 07:57AM	Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive Zacks +9.70%
Mar-18-21 08:57AM	Implied Volatility Surging for Nabriva (NBRV) Stock Options Zacks
Mar-16-21 08:00AM	Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin) GlobeNewswire -8.57%
Mar-11-21 04:07PM	Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates GlobeNewswire
02:30PM	Nabriva Therapeutics Plc to Host Earnings Call ACCESSWIRE
Mar-09-21 07:27AM	Nabriva Therapeutics (NBRV) Is in Oversold Territory: What's Next? Zacks
Mar-03-21 04:05PM	Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021 GlobeNewswire
Mar-01-21 08:00AM	Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire -19.67%
Feb-26-21 08:00AM	Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer GlobeNewswire
Feb-17-21 10:04AM	UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire
Feb-02-21 08:05AM	The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga
Feb-01-21 04:30PM	Nabriva Therapeutics Announces Retirement of its Chief Financial Officer GlobeNewswire
Jan-05-21 04:01PM	Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January GlobeNewswire
Dec-10-20 11:18PM	Nabriva Therapeutics Announces Pricing of $15 Million Public Offering GlobeNewswire
11:05PM	Is NBRV A Good Stock To Buy Now? Insider Monkey
04:01PM	Nabriva Therapeutics Announces Proposed Public Offering GlobeNewswire
Dec-07-20 07:00AM	Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China GlobeNewswire
Dec-02-20 08:00AM	Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split GlobeNewswire -10.50%
Nov-12-20 07:01AM	Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Nov-05-20 04:01PM	Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates GlobeNewswire
02:45PM	Nabriva Therapeutics Plc to Host Earnings Call ACCESSWIRE
Nov-03-20 06:06AM	Some Analysts Just Cut Their Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates Simply Wall St.
Nov-02-20 04:01PM	Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-13-20 07:00AM	Nabrivas XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP) GlobeNewswire +5.24%
Sep-10-20 08:39AM	Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO (fosfomycin) by Centers for Medicare & Medicaid Services GlobeNewswire
Aug-31-20 07:00AM	Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Aug-06-20 04:01PM	Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates GlobeNewswire
Aug-03-20 07:00AM	Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020 GlobeNewswire

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BURGESS DANIEL D	Director	Aug 02	Sale	0.19	11,341	2,156	10,384	Aug 04 06:24 PM
Broom Colin MD	Director	Aug 02	Sale	0.19	5,339	1,015	36,523	Aug 04 06:22 PM
Webster Stephen W	Director	Aug 02	Sale	0.19	7,826	1,487	11,447	Aug 04 06:20 PM
CORRIGAN MARK	Director	Aug 02	Sale	0.19	10,297	1,956	7,203	Aug 04 06:19 PM
Rowland Charles A Jr	Director	Aug 01	Sale	0.17	8,496	1,487	15,277	Aug 03 09:48 PM
Bourdow Carrie L.	Director	Aug 01	Sale	0.17	8,540	1,487	9,933	Aug 03 09:47 PM
Schroeder Theodore R	Chief Executive Officer	Dec 28	Buy	0.57	100,000	57,320	325,879	Dec 29 09:32 PM
Naftzger J. Christopher	General Counsel and Corp Sec	Dec 27	Buy	0.59	7,000	4,130	7,000	Dec 28 07:04 PM
Schroeder Theodore R	Chief Executive Officer	Sep 14	Buy	1.13	50,000	56,500	226,875	Sep 15 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience